Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of VER-01 With/Without Meal in Healthy Volunteers
NCT04930796Phase 1Completed
- Sponsor
- Vertanical
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VER-01 in chronic low back pain (CLBP) (2 arms), sponsored by Vertanical. Primary endpoints: Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-t at Day 4, Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-∞ at Day 4 and 1 more. Started Aug 2022; status: completed.
02
Drugs
VER-01
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT04930796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930796.